RT @BiosimsCouncil: The most extensive literature review available supports confidence in switching from reference to #biosimilar medicines…
Have you seen the results of 90 studies suggesting a low risk of either a safety concern or loss of efficacy after switching to a biosimilar? https://t.co/cjDkSzQB20 #BiosimilarsGoGlobal #AskaboutBiosimilars #BiologicsForAll https://t.co/vhlc7v6zkM
RT @BiosimsCouncil: The most extensive literature review available supports confidence in switching from reference to #biosimilar medicines…
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. - https://t.co/DiBVPiDMj5 #oncology
RT @RevistaMFSamfyc: Cambiar de medicinas de referencia a biosimilares: revisión sistemática de la literatura de resultados clínicos https:…
RT @sefh_: Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. PDF https://t.co/0CyONGbAnc
Have you seen the results of a recent study suggesting little to no safety concern after switching to a #biosimilar? https://t.co/KMLDkTKSiF https://t.co/kA3SyRMQFY
Excelente revisão sistemática sobre Biosimilares. Precisamos melhorar os nossos debates sobre o tema aqui no Brasil. https://t.co/qDoTA7uvOa https://t.co/1pFthBr80L
RT @medicinesforEU: The most extensive literature review available supports confidence in switching from reference to biosimilar medicines…
I biosimilari non sono "banalmente" generici dei farmaci biologici ma molto di più ed aiutano la ricerca scientifica tanto quanto i farmaci originatori https://t.co/GJpzyR1wr4
RT @medicinesforEU: The most extensive literature review available supports confidence in switching from reference to biosimilar medicines…
The most extensive literature review available supports confidence in switching from reference to biosimilar medicines – https://t.co/cjDkSA8bTy #BiosimilarsGoGlobal #AskaboutBiosimilars #BiologicsForAll https://t.co/fYo4PVzjye
RT @sefh_: Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. PDF https://t.co/0CyONGbAnc
RT @sefh_: Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. PDF https://t.co/0CyONGbAnc
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. PDF https://t.co/0CyONGbAnc
Cambiar de medicinas de referencia a biosimilares: revisión sistemática de la literatura de resultados clínicos https://t.co/fxhTqf9cpG PMID 29500555
RT @medicinesforEU: Systematic literature review provides reassurance to healthcare professionals and the public regarding safety of switch…
RT @medicinesforEU: Systematic literature review provides reassurance to healthcare professionals and the public regarding safety of switch…
Systematic literature review provides reassurance to healthcare professionals and the public regarding safety of switching reference medicines to biosimilars https://t.co/cjDkSzQB20 #Biosimilars #BiosimilarsGoGlobal #AskaboutBiosims #BiologicsForAll
RT @BiosimsCouncil: The most extensive literature review available supports confidence in switching from reference to #biosimilar medicines…
RT @Peter_IGL: But of course! No differences in immunogenicity, safety, or efficacy. Reassurance to healthcare professionals and the public…
RT @BiosimsCouncil: The most extensive literature review available supports confidence in switching from reference to #biosimilar medicines…
RT @Peter_IGL: But of course! No differences in immunogenicity, safety, or efficacy. Reassurance to healthcare professionals and the public…
RT @BiosimsCouncil: The most extensive literature review available supports confidence in switching from reference to #biosimilar medicines…
@CABiotecnologia @SoberaniaSalud @fundacion_gep @msalnacion @Ekonsalud @ISALUD_Oficial @PAMI_org_ar @norabar @zlotomarcelo Apoyar desarrollo de industria nacional y terminar monopolios multinacionales(i.e adalimumab Humira) https://t.co/ZmQ7Xe6WeA
RT @BiosimsCouncil: The most extensive literature review available supports confidence in switching from reference to #biosimilar medicines…
But of course! No differences in immunogenicity, safety, or efficacy. Reassurance to healthcare professionals and the public that the risk of immunogenicity-related safety concerns or diminished efficacy is unchanged after switching from a reference biolog
My weekly statement about how important this study is for the #biosimilars industry https://t.co/LuSHG7nemi
The most extensive literature review available supports confidence in switching from reference to #biosimilar medicines. https://t.co/KMLDkTKSiF https://t.co/gsIwllU4Iz
RT @medicinesforEU: Systematic literature review provides reassurance to healthcare professionals and the public regarding safety of switch…
Systematic literature review provides reassurance to healthcare professionals and the public regarding safety of switching reference medicines to biosimilars #Biosimilars #BiosimilarsGoGlobal #AskaboutBiosims #BiologicsForAll https://t.co/cjDkSzQB20
RT @medicinesforEU: Expand your knowledge, read the new publication on switching reference medicines to biosimilars: a systematic literatur…
RT @BrianLehman1: Systematic literature review of 90 switching studies (1993 - 6.30.17) finds that switching from reference biologics to #b…
RT @medicinesforEU: Expand your knowledge, read the new publication on switching reference medicines to biosimilars: a systematic literatur…
RT @medicinesforEU: Expand your knowledge, read the new publication on switching reference medicines to biosimilars: a systematic literatur…
RT @medicinesforEU: Expand your knowledge, read the new publication on switching reference medicines to biosimilars: a systematic literatur…
Expand your knowledge, read the new publication on switching reference medicines to biosimilars: a systematic literature review of clinical outcomes #Biosimilars #BiosimilarsGoGlobal #AskaboutBiosims #BiologicsForAll https://t.co/cjDkSzQB20
RT @BioSim_es: Muy relevante este estudio sobre intercambiabilidad de medicamentos biológicos. Meta-análisis de 90 estudios con 14.225 paci…
RT @BrianLehman1: Systematic literature review of 90 switching studies (1993 - 6.30.17) finds that switching from reference biologics to #b…
RT @BrianLehman1: Systematic literature review of 90 switching studies (1993 - 6.30.17) finds that switching from reference biologics to #b…
RT @BrianLehman1: Systematic literature review of 90 switching studies (1993 - 6.30.17) finds that switching from reference biologics to #b…
RT @BrianLehman1: Systematic literature review of 90 switching studies (1993 - 6.30.17) finds that switching from reference biologics to #b…
RT @velezmeca: El "Switching" entre original y biosimilar. Buena revisión a texto completo https://t.co/fnJoR5EgC4 https://t.co/NZjEDjBwdl
Risk of immunogenicity-related safety concerns or diminished efficacy is unchanged after switching from a reference biologic to a biosimilar; https://t.co/Ds81sHu4Mu
RT @velezmeca: El "Switching" entre original y biosimilar. Buena revisión a texto completo https://t.co/fnJoR5EgC4 https://t.co/NZjEDjBwdl
RT @BrianLehman1: Systematic literature review of 90 switching studies (1993 - 6.30.17) finds that switching from reference biologics to #b…
RT @BrianLehman1: Systematic literature review of 90 switching studies (1993 - 6.30.17) finds that switching from reference biologics to #b…
RT @BrianLehman1: Systematic literature review of 90 switching studies (1993 - 6.30.17) finds that switching from reference biologics to #b…
RT @BrianLehman1: Systematic literature review of 90 switching studies (1993 - 6.30.17) finds that switching from reference biologics to #b…
RT @BrianLehman1: Systematic literature review of 90 switching studies (1993 - 6.30.17) finds that switching from reference biologics to #b…
Systematic literature review of 90 switching studies (1993 - 6.30.17) finds that switching from reference biologics to #biosimilars does not lead to altered clinical outcomes, including enhanced immunogenicity, compromised safety, or diminished efficacy. h
RT @velezmeca: El "Switching" entre original y biosimilar. Buena revisión a texto completo https://t.co/fnJoR5EgC4 https://t.co/NZjEDjBwdl
RT @velezmeca: El "Switching" entre original y biosimilar. Buena revisión a texto completo https://t.co/fnJoR5EgC4 https://t.co/NZjEDjBwdl
Switching Reference Medicines to Biosimilars. Siguiente paso, ¿el multiswitching? https://t.co/uOdngxWxck
RT @velezmeca: El "Switching" entre original y biosimilar. Buena revisión a texto completo https://t.co/fnJoR5EgC4 https://t.co/NZjEDjBwdl
El "Switching" entre original y biosimilar. Buena revisión a texto completo https://t.co/fnJoR5EgC4 https://t.co/NZjEDjBwdl
Biosimilar switching studies show no adverse efficay or safety effects, eesearcher say https://t.co/WdLkUhA8P2
RT @BrianLehman1: Peer reviewed article confirms no diminished efficacy or increased safety concerns when switching to a #biosimilar https:…
Peer reviewed article confirms no diminished efficacy or increased safety concerns when switching to a #biosimilar https://t.co/lLowzwXBzf https://t.co/xk2fLof9sn
RT @DrugsJournal: Biosimilar switching studies show no adverse efficacy or safety effects @DrugsJournal systematic review https://t.co/SFHw…
RT @DrugsJournal: Biosimilar switching studies show no adverse efficacy or safety effects @DrugsJournal systematic review https://t.co/SFHw…
"...these results provide reassurance to healthcare professionals and the public that the risk of immunogenicity-related safety concerns or diminished efficacy is unchanged after switching from a reference biologic to a biosimilar medicine" https://t.co/ab
RT @AnnaRoseWelch: I can't emphasize enough the importance of this new study in the #biosimilar space: "Switching Reference Medicines to Bi…
Biosimilar switching studies show no adverse efficacy or safety effects @DrugsJournal systematic review https://t.co/SFHwaEpcQk
RT @Genericseditor: Important research, putting unfounded fears to rest. Seems Norway's medicines agency was right - we have all the switch…
RT @avalerehealth: Avalere's Gillian Woollett & other experts recently teamed up to examine the efficacy & safety of switching between a bi…
RT @Genericseditor: Important research, putting unfounded fears to rest. Seems Norway's medicines agency was right - we have all the switch…
RT @Genericseditor: Important research, putting unfounded fears to rest. Seems Norway's medicines agency was right - we have all the switch…
Important research, putting unfounded fears to rest. Seems Norway's medicines agency was right - we have all the switching evidence we need. https://t.co/hvTYYqDoZK
Avalere's Gillian Woollett & other experts recently teamed up to examine the efficacy & safety of switching between a biologic & #biosimilar. Their research uncovered no meaningful differences in safety or efficacy. Read the full results here!
RT @BioSim_es: Muy relevante este estudio sobre intercambiabilidad de medicamentos biológicos. Meta-análisis de 90 estudios con 14.225 paci…
RT @BioSim_es: Muy relevante este estudio sobre intercambiabilidad de medicamentos biológicos. Meta-análisis de 90 estudios con 14.225 paci…
RT @BioSim_es: Muy relevante este estudio sobre intercambiabilidad de medicamentos biológicos. Meta-análisis de 90 estudios con 14.225 paci…
Latinoamérica tiene la oportunidad de desarrollar su industria biotecnologica y desarrollar su independencia.@ISALUD_Oficial @fundacion_gep @somosRedLAM @Saludporderecho @FADEPOF @SoberaniaSalud https://t.co/B2Zpk9UDwg
RT @medisien: Results provide reassurance to healthcare professionals & public that the risk of immunogenicity-related safety concerns or d…
RT @BioSim_es: Muy relevante este estudio sobre intercambiabilidad de medicamentos biológicos. Meta-análisis de 90 estudios con 14.225 paci…
RT @rmunozlouis: Nuevos estudios sobre #intercambiabilidad en medicamentos #biologicos https://t.co/FHfgnXLlhB
Nuevos estudios sobre #intercambiabilidad en medicamentos #biologicos https://t.co/FHfgnXLlhB
RT @BioSim_es: Muy relevante este estudio sobre intercambiabilidad de medicamentos biológicos. Meta-análisis de 90 estudios con 14.225 paci…
RT @BioSim_es: Muy relevante este estudio sobre intercambiabilidad de medicamentos biológicos. Meta-análisis de 90 estudios con 14.225 paci…
Muy relevante este estudio sobre intercambiabilidad de medicamentos biológicos. Meta-análisis de 90 estudios con 14.225 pacientes únicos. La gran mayoría de las publicaciones no informaron diferencias en inmunogenicidad, seguridad o eficacia. https://t.co
Results provide reassurance to healthcare professionals & public that the risk of immunogenicity-related safety concerns or diminished efficacy is unchanged after switching from a reference biologic to a biosimilar medicine. @msalnacion @ISALUD_Oficial
RT @AnnaRoseWelch: I can't emphasize enough the importance of this new study in the #biosimilar space: "Switching Reference Medicines to Bi…
RT @AnnaRoseWelch: I can't emphasize enough the importance of this new study in the #biosimilar space: "Switching Reference Medicines to Bi…
I can't emphasize enough the importance of this new study in the #biosimilar space: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes." https://t.co/s7Cv3VKfBN